Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application, Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within Immediate
Biosimulation Market Growth & Trends
The global biosimulation market size is expected treach USD 10.0 billion by 2030, according ta new report by Grand View Research, Inc. The market is expected texpand at a CAGR of 17.0% from 2025 t2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.
The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads tan increase in the cost of clinical trials, which is expected tdrive the clinical urgency tincorporate in silicbiology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.
A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs ttreat diseases such as AIDS have led thigh clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.
The COVID-19 pandemic alshad a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance tany organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely tdisrupt the supply chain and adversely impact its business and financial performance.
Surging demand for biosimulation software and services can alsbe attributed ttheir higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.
Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, tmaintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed tadd a critical new species tits GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired InsilicBiotechnology AG, a Germany-based company that develops and provides bioprocess software and services.
Biosimulation Market Report Highlights
Biosimulation Market Growth & Trends
The global biosimulation market size is expected treach USD 10.0 billion by 2030, according ta new report by Grand View Research, Inc. The market is expected texpand at a CAGR of 17.0% from 2025 t2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.
The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads tan increase in the cost of clinical trials, which is expected tdrive the clinical urgency tincorporate in silicbiology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.
A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs ttreat diseases such as AIDS have led thigh clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.
The COVID-19 pandemic alshad a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance tany organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely tdisrupt the supply chain and adversely impact its business and financial performance.
Surging demand for biosimulation software and services can alsbe attributed ttheir higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.
Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, tmaintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed tadd a critical new species tits GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired InsilicBiotechnology AG, a Germany-based company that develops and provides bioprocess software and services.
Biosimulation Market Report Highlights
- Software dominated the market, with a revenue share of 62.02% in 2024. This can be attributed tthe availability of application-specific software catering tspecific research and development requirements.
- The drug development segment held the largest market share of 55.43% in 2024, driven by the increasing number of drug development processes.
- Oncology held the largest revenue share in 2024. In oncology, biosimulation is crucial in understanding tumor dynamics, treatment responses, and patient-specific factors influencing cancer outcomes.
- Cloud-based deployment model dominated the market and held the largest revenue share of over 43.00% in 2024 and is expected tgrow at the fastest CAGR during the forecast period.
- License-based model held the largest revenue share in 2024. The advantage of this model is that it provides users with access tsophisticated tools without the need for substantial investments in infrastructure or development.
- Life science companies accounted for the largest revenue share in 2024. These companies are increasingly adopting biosimulation software as a critical tool in drug development and research.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Application Segment
1.2.3. Therapeutic Area Segment
1.2.4. Deployment Model Segment
1.2.5. Pricing Model Segment
1.2.6. End Use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective
1.10.2. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
CHAPTER 3. BIOSIMULATION MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of chronic diseases
3.2.1.2. Growing demand for personalized medicine
3.2.1.3. Technological advancements
3.2.2. Market restraint analysis
3.2.2.1. High cost associated with biosimulation technology and software
3.2.2.2. Stringent regulatory requirements
3.3. Biosimulation Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.2.4. Environmental Landscape
3.3.2.5. Legal Landscape
3.3.2.6. Social Landscape
3.4. COVID-19 Impact Analysis
CHAPTER 4. BIOSIMULATION MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Global Biosimulation Market Product Movement Analysis
4.3. Global Biosimulation Market Size & Trend Analysis, by Product, 2018 - 2030 (USD Million)
4.4. Software
4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2. Molecular Modeling & Simulation Software
4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.3. Clinical Trial Design Software
4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.4. PK/PD Modeling and Simulation Software
4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.5. Pbpk Modeling and Simulation Software
4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.6. Toxicity Prediction Software
4.4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.7. Other Software
4.4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.5. Services
4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.5.2. Contract Services
4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.5.3. Consulting
4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.5.4. Other (Implementation, Training, & Support, etc.)
4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 5. BIOSIMULATION MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Global Biosimulation Market Application Movement Analysis
5.3. Global Biosimulation Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
5.4. Drug Discovery & Development
5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.5. Disease Modeling
5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.6. Other (Precision Medicine, Toxicology, etc.)
5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 6. BIOSIMULATION MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Global Biosimulation Market Therapeutic Area Movement Analysis
6.3. Global Biosimulation Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
6.4. Oncology
6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.5. Cardiovascular Disease
6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.6. Infectious Disease
6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.7. Neurological Disorders
6.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.8. Others
6.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 7. BIOSIMULATION MARKET: DEPLOYMENT MODEL ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Global Biosimulation Market Deployment Model Movement Analysis
7.3. Global Biosimulation Market Size & Trend Analysis, by Deployment Model, 2018 - 2030 (USD Million)
7.4. Cloud-based
7.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.5. On-premises
7.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Hybrid Model
7.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 8. BIOSIMULATION MARKET: PRICING MODEL ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Global Biosimulation Market Pricing Model Movement Analysis
8.3. Global Biosimulation Market Size & Trend Analysis, by Pricing Model, 2018 - 2030 (USD Million)
8.4. License-based Model
8.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.5. Subscription-based Model
8.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.6. Service-based Model
8.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.7. Pay Per Use Model
8.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 9. BIOSIMULATION MARKET: END USE ESTIMATES & TREND ANALYSIS
9.1. Segment Dashboard
9.2. Global Biosimulation Market End Use Movement Analysis
9.3. Global Biosimulation Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
9.4. Life Science Companies
9.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.4.2. Pharmaceutical Companies
9.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.4.3. Biopharma Companies
9.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.4.4. Medical Device Companies
9.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.4.5. CROs/CDMOs
9.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.5. Academic Research Institutions
9.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.6. Others (Regulatory Authorities, etc.)
9.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 10. BIOSIMULATION MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
10.1. Regional Market Share Analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
10.4. North America
10.4.1. U.S.
10.4.1.1. Key country dynamics
10.4.1.2. Regulatory framework
10.4.1.3. Competitive scenario
10.4.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
10.4.2. Canada
10.4.2.1. Key country dynamics
10.4.2.2. Regulatory framework
10.4.2.3. Competitive scenario
10.4.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
10.4.3. Mexico
10.4.3.1. Key country dynamics
10.4.3.2. Regulatory framework
10.4.3.3. Competitive scenario
10.4.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
10.5. Europe
10.5.1. UK
10.5.1.1. Key country dynamics
10.5.1.2. Regulatory framework
10.5.1.3. Competitive scenario
10.5.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
10.5.2. Germany
10.5.2.1. Key country dynamics
10.5.2.2. Regulatory framework
10.5.2.3. Competitive scenario
10.5.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
10.5.3. France
10.5.3.1. Key country dynamics
10.5.3.2. Regulatory framework
10.5.3.3. Competitive scenario
10.5.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
10.5.4. Italy
10.5.4.1. Key country dynamics
10.5.4.2. Regulatory framework
10.5.4.3. Competitive scenario
10.5.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
10.5.5. Spain
10.5.5.1. Key country dynamics
10.5.5.2. Regulatory framework
10.5.5.3. Competitive scenario
10.5.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
10.5.6. Norway
10.5.6.1. Key country dynamics
10.5.6.2. Regulatory framework
10.5.6.3. Competitive scenario
10.5.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
10.5.7. Sweden
10.5.7.1. Key country dynamics
10.5.7.2. Regulatory framework
10.5.7.3. Competitive scenario
10.5.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
10.5.8. Denmark
10.5.8.1. Key country dynamics
10.5.8.2. Regulatory framework
10.5.8.3. Competitive scenario
10.5.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
10.6. Asia Pacific
10.6.1. Japan
10.6.1.1. Key country dynamics
10.6.1.2. Regulatory framework
10.6.1.3. Competitive scenario
10.6.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
10.6.2. China
10.6.2.1. Key country dynamics
10.6.2.2. Regulatory framework
10.6.2.3. Competitive scenario
10.6.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
10.6.3. India
10.6.3.1. Key country dynamics
10.6.3.2. Regulatory framework
10.6.3.3. Competitive scenario
10.6.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
10.6.4. Australia
10.6.4.1. Key country dynamics
10.6.4.2. Regulatory framework
10.6.4.3. Competitive scenario
10.6.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
10.6.5. South Korea
10.6.5.1. Key country dynamics
10.6.5.2. Regulatory framework
10.6.5.3. Competitive scenario
10.6.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
10.6.6. Thailand
10.6.6.1. Key country dynamics
10.6.6.2. Regulatory framework
10.6.6.3. Competitive scenario
10.6.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
10.7. Latin America
10.7.1. Brazil
10.7.1.1. Key country dynamics
10.7.1.2. Regulatory framework
10.7.1.3. Competitive scenario
10.7.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
10.7.2. Argentina
10.7.2.1. Key country dynamics
10.7.2.2. Regulatory framework
10.7.2.3. Competitive scenario
10.7.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
10.8. MEA
10.8.1. South Africa
10.8.1.1. Key country dynamics
10.8.1.2. Regulatory framework
10.8.1.3. Competitive scenario
10.8.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
10.8.2. Saudi Arabia
10.8.2.1. Key country dynamics
10.8.2.2. Regulatory framework
10.8.2.3. Competitive scenario
10.8.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
10.8.3. UAE
10.8.3.1. Key country dynamics
10.8.3.2. Regulatory framework
10.8.3.3. Competitive scenario
10.8.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
10.8.4. Kuwait
10.8.4.1. Key country dynamics
10.8.4.2. Regulatory framework
10.8.4.3. Competitive scenario
10.8.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Company/Competition Categorization
11.2. Strategy Mapping
11.3. Company Market Position/Share Analysis, 2024
11.4. Company Profiles/Listing
11.4.1. Certara, USA
11.4.1.1. Company overview
11.4.1.2. Financial performance
11.4.1.3. Product benchmarking
11.4.1.4. Strategic initiatives
11.4.2. Dassault Syst?mes
11.4.2.1. Company overview
11.4.2.2. Financial performance
11.4.2.3. Product benchmarking
11.4.2.4. Strategic initiatives
11.4.3. Advanced Chemistry Development
11.4.3.1. Company overview
11.4.3.2. Financial performance
11.4.3.3. Product benchmarking
11.4.3.4. Strategic initiatives
11.4.4. Simulation Plus
11.4.4.1. Company overview
11.4.4.2. Financial performance
11.4.4.3. Product benchmarking
11.4.4.4. Strategic initiatives
11.4.5. Schrodinger, Inc.
11.4.5.1. Company overview
11.4.5.2. Financial performance
11.4.5.3. Product benchmarking
11.4.5.4. Strategic initiatives
11.4.6. Chemical Computing Group ULC
11.4.6.1. Company overview
11.4.6.2. Financial performance
11.4.6.3. Product benchmarking
11.4.6.4. Strategic initiatives
11.4.7. Physiomics Plc
11.4.7.1. Company overview
11.4.7.2. Financial performance
11.4.7.3. Product benchmarking
11.4.7.4. Strategic initiatives
11.4.8. Rosa & Co. LLC
11.4.8.1. Company overview
11.4.8.2. Financial performance
11.4.8.3. Product benchmarking
11.4.8.4. Strategic initiatives
11.4.9. BioSimulation Consulting Inc.
11.4.9.1. Company overview
11.4.9.2. Financial performance
11.4.9.3. Product benchmarking
11.4.9.4. Strategic initiatives
11.4.10. Genedata AG
11.4.10.1. Company overview
11.4.10.2. Financial performance
11.4.10.3. Product benchmarking
11.4.10.4. Strategic initiatives
11.4.11. Instem Group of Companies
11.4.11.1. Company overview
11.4.11.2. Financial performance
11.4.11.3. Product benchmarking
11.4.11.4. Strategic initiatives
11.4.12. PPD, Inc.
11.4.12.1. Company overview
11.4.12.2. Financial performance
11.4.12.3. Product benchmarking
11.4.12.4. Strategic initiatives
11.4.13. Yokogawa Insilico Biotechnology GmbH
11.4.13.1. Company overview
11.4.13.2. Financial performance
11.4.13.3. Product benchmarking
11.4.13.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product Segment
1.2.2. Application Segment
1.2.3. Therapeutic Area Segment
1.2.4. Deployment Model Segment
1.2.5. Pricing Model Segment
1.2.6. End Use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective
1.10.2. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
CHAPTER 3. BIOSIMULATION MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of chronic diseases
3.2.1.2. Growing demand for personalized medicine
3.2.1.3. Technological advancements
3.2.2. Market restraint analysis
3.2.2.1. High cost associated with biosimulation technology and software
3.2.2.2. Stringent regulatory requirements
3.3. Biosimulation Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.2.4. Environmental Landscape
3.3.2.5. Legal Landscape
3.3.2.6. Social Landscape
3.4. COVID-19 Impact Analysis
CHAPTER 4. BIOSIMULATION MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Global Biosimulation Market Product Movement Analysis
4.3. Global Biosimulation Market Size & Trend Analysis, by Product, 2018 - 2030 (USD Million)
4.4. Software
4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.2. Molecular Modeling & Simulation Software
4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.3. Clinical Trial Design Software
4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.4. PK/PD Modeling and Simulation Software
4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.5. Pbpk Modeling and Simulation Software
4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.6. Toxicity Prediction Software
4.4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.4.7. Other Software
4.4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.5. Services
4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.5.2. Contract Services
4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.5.3. Consulting
4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
4.5.4. Other (Implementation, Training, & Support, etc.)
4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 5. BIOSIMULATION MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Global Biosimulation Market Application Movement Analysis
5.3. Global Biosimulation Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
5.4. Drug Discovery & Development
5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.5. Disease Modeling
5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
5.6. Other (Precision Medicine, Toxicology, etc.)
5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 6. BIOSIMULATION MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Global Biosimulation Market Therapeutic Area Movement Analysis
6.3. Global Biosimulation Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
6.4. Oncology
6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.5. Cardiovascular Disease
6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.6. Infectious Disease
6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.7. Neurological Disorders
6.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
6.8. Others
6.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 7. BIOSIMULATION MARKET: DEPLOYMENT MODEL ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Global Biosimulation Market Deployment Model Movement Analysis
7.3. Global Biosimulation Market Size & Trend Analysis, by Deployment Model, 2018 - 2030 (USD Million)
7.4. Cloud-based
7.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.5. On-premises
7.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Hybrid Model
7.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 8. BIOSIMULATION MARKET: PRICING MODEL ESTIMATES & TREND ANALYSIS
8.1. Segment Dashboard
8.2. Global Biosimulation Market Pricing Model Movement Analysis
8.3. Global Biosimulation Market Size & Trend Analysis, by Pricing Model, 2018 - 2030 (USD Million)
8.4. License-based Model
8.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.5. Subscription-based Model
8.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.6. Service-based Model
8.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
8.7. Pay Per Use Model
8.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 9. BIOSIMULATION MARKET: END USE ESTIMATES & TREND ANALYSIS
9.1. Segment Dashboard
9.2. Global Biosimulation Market End Use Movement Analysis
9.3. Global Biosimulation Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
9.4. Life Science Companies
9.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.4.2. Pharmaceutical Companies
9.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.4.3. Biopharma Companies
9.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.4.4. Medical Device Companies
9.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.4.5. CROs/CDMOs
9.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.5. Academic Research Institutions
9.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
9.6. Others (Regulatory Authorities, etc.)
9.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 10. BIOSIMULATION MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
10.1. Regional Market Share Analysis, 2024 & 2030
10.2. Regional Market Dashboard
10.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
10.4. North America
10.4.1. U.S.
10.4.1.1. Key country dynamics
10.4.1.2. Regulatory framework
10.4.1.3. Competitive scenario
10.4.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
10.4.2. Canada
10.4.2.1. Key country dynamics
10.4.2.2. Regulatory framework
10.4.2.3. Competitive scenario
10.4.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
10.4.3. Mexico
10.4.3.1. Key country dynamics
10.4.3.2. Regulatory framework
10.4.3.3. Competitive scenario
10.4.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
10.5. Europe
10.5.1. UK
10.5.1.1. Key country dynamics
10.5.1.2. Regulatory framework
10.5.1.3. Competitive scenario
10.5.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
10.5.2. Germany
10.5.2.1. Key country dynamics
10.5.2.2. Regulatory framework
10.5.2.3. Competitive scenario
10.5.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
10.5.3. France
10.5.3.1. Key country dynamics
10.5.3.2. Regulatory framework
10.5.3.3. Competitive scenario
10.5.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
10.5.4. Italy
10.5.4.1. Key country dynamics
10.5.4.2. Regulatory framework
10.5.4.3. Competitive scenario
10.5.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
10.5.5. Spain
10.5.5.1. Key country dynamics
10.5.5.2. Regulatory framework
10.5.5.3. Competitive scenario
10.5.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
10.5.6. Norway
10.5.6.1. Key country dynamics
10.5.6.2. Regulatory framework
10.5.6.3. Competitive scenario
10.5.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
10.5.7. Sweden
10.5.7.1. Key country dynamics
10.5.7.2. Regulatory framework
10.5.7.3. Competitive scenario
10.5.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
10.5.8. Denmark
10.5.8.1. Key country dynamics
10.5.8.2. Regulatory framework
10.5.8.3. Competitive scenario
10.5.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
10.6. Asia Pacific
10.6.1. Japan
10.6.1.1. Key country dynamics
10.6.1.2. Regulatory framework
10.6.1.3. Competitive scenario
10.6.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
10.6.2. China
10.6.2.1. Key country dynamics
10.6.2.2. Regulatory framework
10.6.2.3. Competitive scenario
10.6.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
10.6.3. India
10.6.3.1. Key country dynamics
10.6.3.2. Regulatory framework
10.6.3.3. Competitive scenario
10.6.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
10.6.4. Australia
10.6.4.1. Key country dynamics
10.6.4.2. Regulatory framework
10.6.4.3. Competitive scenario
10.6.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
10.6.5. South Korea
10.6.5.1. Key country dynamics
10.6.5.2. Regulatory framework
10.6.5.3. Competitive scenario
10.6.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
10.6.6. Thailand
10.6.6.1. Key country dynamics
10.6.6.2. Regulatory framework
10.6.6.3. Competitive scenario
10.6.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
10.7. Latin America
10.7.1. Brazil
10.7.1.1. Key country dynamics
10.7.1.2. Regulatory framework
10.7.1.3. Competitive scenario
10.7.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
10.7.2. Argentina
10.7.2.1. Key country dynamics
10.7.2.2. Regulatory framework
10.7.2.3. Competitive scenario
10.7.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
10.8. MEA
10.8.1. South Africa
10.8.1.1. Key country dynamics
10.8.1.2. Regulatory framework
10.8.1.3. Competitive scenario
10.8.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
10.8.2. Saudi Arabia
10.8.2.1. Key country dynamics
10.8.2.2. Regulatory framework
10.8.2.3. Competitive scenario
10.8.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
10.8.3. UAE
10.8.3.1. Key country dynamics
10.8.3.2. Regulatory framework
10.8.3.3. Competitive scenario
10.8.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
10.8.4. Kuwait
10.8.4.1. Key country dynamics
10.8.4.2. Regulatory framework
10.8.4.3. Competitive scenario
10.8.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 11. COMPETITIVE LANDSCAPE
11.1. Company/Competition Categorization
11.2. Strategy Mapping
11.3. Company Market Position/Share Analysis, 2024
11.4. Company Profiles/Listing
11.4.1. Certara, USA
11.4.1.1. Company overview
11.4.1.2. Financial performance
11.4.1.3. Product benchmarking
11.4.1.4. Strategic initiatives
11.4.2. Dassault Syst?mes
11.4.2.1. Company overview
11.4.2.2. Financial performance
11.4.2.3. Product benchmarking
11.4.2.4. Strategic initiatives
11.4.3. Advanced Chemistry Development
11.4.3.1. Company overview
11.4.3.2. Financial performance
11.4.3.3. Product benchmarking
11.4.3.4. Strategic initiatives
11.4.4. Simulation Plus
11.4.4.1. Company overview
11.4.4.2. Financial performance
11.4.4.3. Product benchmarking
11.4.4.4. Strategic initiatives
11.4.5. Schrodinger, Inc.
11.4.5.1. Company overview
11.4.5.2. Financial performance
11.4.5.3. Product benchmarking
11.4.5.4. Strategic initiatives
11.4.6. Chemical Computing Group ULC
11.4.6.1. Company overview
11.4.6.2. Financial performance
11.4.6.3. Product benchmarking
11.4.6.4. Strategic initiatives
11.4.7. Physiomics Plc
11.4.7.1. Company overview
11.4.7.2. Financial performance
11.4.7.3. Product benchmarking
11.4.7.4. Strategic initiatives
11.4.8. Rosa & Co. LLC
11.4.8.1. Company overview
11.4.8.2. Financial performance
11.4.8.3. Product benchmarking
11.4.8.4. Strategic initiatives
11.4.9. BioSimulation Consulting Inc.
11.4.9.1. Company overview
11.4.9.2. Financial performance
11.4.9.3. Product benchmarking
11.4.9.4. Strategic initiatives
11.4.10. Genedata AG
11.4.10.1. Company overview
11.4.10.2. Financial performance
11.4.10.3. Product benchmarking
11.4.10.4. Strategic initiatives
11.4.11. Instem Group of Companies
11.4.11.1. Company overview
11.4.11.2. Financial performance
11.4.11.3. Product benchmarking
11.4.11.4. Strategic initiatives
11.4.12. PPD, Inc.
11.4.12.1. Company overview
11.4.12.2. Financial performance
11.4.12.3. Product benchmarking
11.4.12.4. Strategic initiatives
11.4.13. Yokogawa Insilico Biotechnology GmbH
11.4.13.1. Company overview
11.4.13.2. Financial performance
11.4.13.3. Product benchmarking
11.4.13.4. Strategic initiatives
